These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 8648881)

  • 1. Granulocyte activation in restenosis after percutaneous transluminal coronary angioplasty.
    Tsutsui M; Shimokawa H; Tanaka S; Yoshihara S; Higuchi S; Matsuguchi T; Okamatsu S
    Jpn Circ J; 1996 Jan; 60(1):27-34. PubMed ID: 8648881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early decrease in minimal luminal diameter after successful percutaneous transluminal coronary angioplasty predicts late restenosis.
    Rodriguez A; Santaera O; Larribeau M; Sosa MI; Palacios IF
    Am J Cardiol; 1993 Jun; 71(16):1391-5. PubMed ID: 8517382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
    Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R
    Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologic response to gain and loss in coronary minimal luminal diameter in patients treated with coronary angioplasty: prediction of restenosis on the basis of exercise capacity.
    Jørgensen B; Simonsen S; Endresen K; Forfang K; Egeland T; Thaulow E
    Am Heart J; 2000 Mar; 139(3):482-90. PubMed ID: 10689263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial.
    Yokoi H; Daida H; Kuwabara Y; Nishikawa H; Takatsu F; Tomihara H; Nakata Y; Kutsumi Y; Ohshima S; Nishiyama S; Seki A; Kato K; Nishimura S; Kanoh T; Yamaguchi H
    J Am Coll Cardiol; 1997 Oct; 30(4):855-62. PubMed ID: 9316509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.
    Tsuchikane E; Fukuhara A; Kobayashi T; Kirino M; Yamasaki K; Kobayashi T; Izumi M; Otsuji S; Tateyama H; Sakurai M; Awata N
    Circulation; 1999 Jul; 100(1):21-6. PubMed ID: 10393676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early alteration of coronary hemodynamics in late restenosis after coronary angioplasty.
    Wu TC; Chen JW; Chen CI; Mar GY; Hsu NW; Chen YH; Ding YA; Wang SP; Chang MS
    Jpn Heart J; 1999 Sep; 40(5):535-48. PubMed ID: 10888374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group.
    Foley DP; Bonnier H; Jackson G; Macaya C; Shepherd J; Vrolix M; Serruys PW
    Am J Cardiol; 1994 May; 73(14):50D-61D. PubMed ID: 8198025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of an acute reduction in lipoprotein(a) with coronary artery restenosis after percutaneous transluminal coronary angioplasty.
    Horie H; Takahashi M; Izumi M; Takaoka A; Fujita T; Sakamoto T; Kito O; Okamura H; Kinoshita M
    Circulation; 1997 Jul; 96(1):166-73. PubMed ID: 9236431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased plasma antigen levels of monocyte chemoattractant protein-1 in patients with restenosis after percutaneous transluminal coronary angioplasty.
    Hokimoto S; Ogawa H; Saito T; Oshima S; Noda K; Soejima H; Takazoe K; Date H; Ishibashi F; Nakamura S; Yasue H
    Jpn Circ J; 2000 Nov; 64(11):831-4. PubMed ID: 11110426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Identification of predictive factors associated with recurrent restenosis after second percutaneous transluminal coronary angioplasty].
    Kishi K; Hiasa Y; Tanaka H; Kinoshita M; Tanimoto M; Wada T; Aihara T
    J Cardiol; 1997 Jan; 29(1):7-12. PubMed ID: 9023674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prior restenosis predicts restenosis after coronary angioplasty of a new significant narrowing.
    Bresee SJ; Jacobs AK; Garber GR; Ruocco NA; Mills RM; Bergelson BA; Ryan TJ; Faxon DP
    Am J Cardiol; 1991 Nov; 68(11):1158-62. PubMed ID: 1951074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation between the deletion polymorphism of the angiotensin-converting enzyme gene and late luminal narrowing after coronary angioplasty.
    Hamon M; Bauters C; Amant C; McFadden EP; Helbecque N; Lablanche JM; Bertrand ME; Amouyel P
    Circulation; 1995 Aug; 92(3):296-9. PubMed ID: 7634441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyte activation after coronary angioplasty in humans.
    De Servi S; Mazzone A; Ricevuti G; Fioravanti A; Bramucci E; Angoli L; Stefano G; Specchia G
    Circulation; 1990 Jul; 82(1):140-6. PubMed ID: 2163778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restenosis after coronary angioplasty for rapidly progressive coronary stenosis.
    Bauters C; Passart F; Lablanche JM; McFadden EP; Hamon M; Bertrand ME
    Eur Heart J; 1996 Nov; 17(11):1671-7. PubMed ID: 8922915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chlamydia pneumoniae seropositivity predicts the risk of restenosis after percutaneous transluminal coronary angioplasty.
    Hayashida K; Tanaka M; Morita H; Hayashi F; Inada T; Suzuki H; Sakamoto T; Katsuragawa M; Hibino H; Kambara H
    Heart Vessels; 2002 May; 16(4):137-45. PubMed ID: 12224784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous transluminal coronary angioplasty (PTCA).
    DeMaio SJ; King SB; Lembo NJ; Roubin GS; Hearn JA; Bhagavan HN; Sgoutas DS
    J Am Coll Nutr; 1992 Feb; 11(1):68-73. PubMed ID: 1541798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months.
    Serruys PW; Luijten HE; Beatt KJ; Geuskens R; de Feyter PJ; van den Brand M; Reiber JH; ten Katen HJ; van Es GA; Hugenholtz PG
    Circulation; 1988 Feb; 77(2):361-71. PubMed ID: 2962786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced secretion of insulin plays a role in the development of atherosclerosis and restenosis of coronary arteries: elective percutaneous transluminal coronary angioplasty in patients with effort angina.
    Nishimoto Y; Miyazaki Y; Toki Y; Murakami R; Shinoda M; Fukushima A; Kanayama H
    J Am Coll Cardiol; 1998 Nov; 32(6):1624-9. PubMed ID: 9822088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
    Hermans WR; Rensing BJ; Foley DP; Tijssen JG; Rutsch W; Emanuelsson H; Danchin N; Wijns W; Chappuis F; Serruys PW
    J Cardiovasc Pharmacol; 1993; 22 Suppl 4():S45-57. PubMed ID: 7523772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.